Compare NetEase Inc (NTES) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs Natera Inc. Common Stock — how do they compare? NetEase Inc trades at $124.18 (market cap $79.76B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: NetEase Inc is the larger of the two by market cap, and NetEase Inc pays a 2.35% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold NetEase Inc for 73 Days and Natera Inc. Common Stock for 0 Days on average.
| NTES | NTRA | |
|---|---|---|
Market Cap | $79.76B | $57.03B |
Volume | 503,697 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $152.85 | $425.64 |
52-Week Low | $109.26 | $179.42 |
Typical Hold Time | 73 Days | 0 Days |
Enterprise Value | $55.44B | $56.18B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTES trades at $123.73, down 1.34% on the day, with a bullish technical signal from moving averages and oscillators. The company reported Q2 2026 revenue of $4.4 billion, an 8% year-over-year increase, though EPS missed expectations. Strong fundamentals include a 27.88% net income margin and robust cash flow from operations of $50.74 billion in 2025. Recent news highlights global expansion and AI investments as key growth drivers.
The outlook remains positive with an 81.82% analyst buy rating and a consensus price target of $168.00, implying significant upside. Key risks include earnings volatility, competitive pressures in gaming, and macroeconomic sensitivity. The stock's current valuation at a P/E of 16.58 offers a reasonable entry point for long-term growth investors.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
